HIT

Health In Tech recognized among the 100 highest-scoring U.S. public mid-market companies following an initial review of approximately 4,300 companies, based on financial strength, workforce performance, innovation and sustainability STUART, Fla., Sept. 9, 2026 /PRNewswire/ -- Health In Tech, Inc. (Nasdaq: HIT), an AI-enabled InsurTech platform company, announced today that it has been named one of Newsweek's America's Greatest Mid-Market Companies 2026.

Health In Tech, Inc. (HIT) Q2 2026 Earnings Call Transcript

Health In Tech NASDAQ: HIT reported second-quarter revenue of $8.1 million, down 13.5% from $9.3 million in the year-earlier period, as the company said the onboarding of a new carrier shifted certain policy effective dates into later quarters.

Contracted Revenue of $32.3 Million as of June 30, 2026 Pipeline Revenue of $66.3 Million as of July 31, 2026 Distribution Partners Grew 19.9% Year Over Year STUART, Fla., Aug. 13, 2026 /PRNewswire/ -- Health In Tech, Inc. (Nasdaq: HIT) ("Health In Tech" or the "Company"), an AI-enabled InsurTech platform company, today announced its unaudited financial results for the three and six months ended June 30, 2026.

STUART, Fla., Aug. 3, 2026 /PRNewswire/ -- Health In Tech, Inc. (Nasdaq: HIT), an AI-enabled InsurTech platform company, today announced that it will release financial results for the second quarter ended June 30, 2026, following the close of market on Wednesday, August 13, 2026.

STUART, Fla., June 29, 2026 /PRNewswire/ -- Health In Tech, Inc. (Nasdaq: HIT) ("Health In Tech" or the "Company") was added as a member of the Russell Microcap® Index, effective when the U.S. market opens on June 29, 2026, as part of the 2026 Russell U.S. indexes reconstitution.

Health In Tech, Inc. (HIT) Q1 2026 Earnings Call Transcript

Reiterates Guidance for 2026 Annual Revenue Ranging between $45 Million and $50 Million STUART, Fla., May 13, 2026 /PRNewswire/ -- Health In Tech, Inc. (Nasdaq: HIT) ("Health In Tech" or "Company"), an AI-enabled InsurTech platform company, today announced its unaudited financial results for the three months ended March 31, 2026.

STUART, Fla., April 30, 2026 /PRNewswire/ -- Health In Tech, Inc. (Nasdaq: HIT), an AI-enabled InsurTech platform company, today announced that it will release financial results for the first quarter ended March 31, 2026, following the close of market on Wednesday, May 13, 2026.

FDA provided critical guidance for the advancement of CAD-1005 to pivotal Phase 3 in HIT Phase 2 data showed a greater than 25% absolute reduction in thrombotic events when CAD-1005 was added to standard anticoagulant therapy PONTE VEDRA, Fla., April 30, 2026 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing innovative treatments for life-threatening immune and thrombotic conditions, today announced a major regulatory milestone after successfully completing its End-of-Phase 2 (EOP2) meeting with the U.S. Food and Drug Administration (FDA) and receiving guidance on key elements of the Phase 3 pivotal trial for CAD-1005, the Company's investigational first-in-class 12-lipoxygenase (12-LOX) inhibitor for heparin-induced thrombocytopenia (HIT).